

Covid-19 Induced Telogen Effluvium And The Role Of A Novel Biomimetic Peptide Hair Growth Formulation In The Management Of Telogen Effluvium

Dr. Debraj Shome, MD, FACS, FRCS, MBA | Dr. Monika Surana, MDS | Dr. Rinky Kapoor, MD



AMERICAN ACADEMY OF COSMETIC SURGERY

Financial Disclosure

- The authors have been one of the founding members of the Research team behind patent of QR678 Neo® hair growth formulation.
- The Novel biomimetic peptide molecule called QR678 Neo® has been used in this study for Covid-19 induced persistent Telogen Effluvium.

About QR678


OVERCOMING THE BARRIERS, CHALLENGES AND UNCERTAINTIES

- Patented in USA
- Patented in India
- FDA approved in 10+ countries



The QR678 Neo Formulation

PLANT DERIVED BIOMIMETIC POLYPEPTIDES (Ubiquitous, Upregulated, Upscaled)



Published Research Papers

Background

Telogen Effluvium in a post Covid-19 patient causes excessive shedding of hair. No definite treatment is available till now. Past studies suggest that QR678Neo® has shown promising results in various types of Alopecia.

Introduction

- Nonspecific reaction pattern of hair loss with increased shedding of telogen hair that developed after 3-4 months of the causing event.
- Covid-19 is known to cause physiological and psychological stress.

Material & Method

Prospective clinical, single-blind study was conducted from September 2020 to May 2021 after seeking approval from the Institutional Ethics Committee.

Inclusion Criteria

- Patient presenting between the ages of 20- 50 years after recovery from RT-PCR proven Covid-19 infection with sustained hair fall even after 6 months.
- Patients having noticeable increased hair loss, and loosing hair in bulk.


Exclusion Criteria

- Hair loss from before suffering with Covid 19 infection.
- Any other type of alopecia other than elogen Effluvium.
- Females who are pregnant or lactating.
- Patients on consumption of oral Finasteride/spironolactone, Minoxidil and/or oral contraceptives.
- Patients with medical disease or on drugs which affect hair loss.


Injection Technique

- At each visit, 1.5 mL of QR678Neo® solution was administered into the scalp.
- Using a 31-G needle and the **nappage technique**.
- Total 8 sessions.


Results




Videomicroscopic Assessment




Global photographic assessment



Adverse Effects



Patient Satisfaction Score



Conclusion

- The Covid-19 stress induced persistent Telogen Effluvium can be daunting on the patients post Covid -19.
- Treatment modalities currently present, fail to give justice to this new onset factor of excessive hair loss due to Covid-19.
- Present study suggests a definitive and quantifiable role of QR678Neo® hair growth formulation in the Covid-19 induced persistent Telogen Effluvium patients for significant improvement in hair density and hair count, and also reduces the hair fall.

References

- Grover C, Khurana A. Telogen effluvium. Indian Journal of Dermatology, Venereology, and Leprology. 2013;79:591.
- Rebora A. Telogen Effluvium: A Comprehensive Review. Clinical, Cosmetic and Investigational Dermatology. 2019;12:583-590.
- Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018;20:369-379.